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Summary 
In this review we will focus on external factors that may modify energy metabolism 
in human skeletal muscle cells (myotubes) and the ability of the myotubes to switch 
between lipid and glucose oxidation. We describe the metabolic parameters 
suppressibility, adaptability and substrate-regulated flexibility and show the influence 
of nutrients such as fatty acids and glucose (chronic hyperglycemia), and some 
pharmacological agents modifying nuclear receptors (PPAR and LXR), on these 
parameters in human myotubes. Possible cellular mechanisms for changes in these 
parameters will also be highlighted. 
 
Metabolic flexibility 
Skeletal muscle is the main tissue involved in lipid and glucose oxidation in the body. 
In the postprandial state glucose oxidation dominates, however fat oxidation increases 
both during fasting and sustained exercise [1-3]. The ability to switch from 
predominantly lipid oxidation during fasting conditions to increased glucose oxidation 
and suppression of lipid oxidation in response to insulin [2, 3] is called metabolic 
flexibility, and is a characteristic of healthy skeletal muscle [4, 5]. Kelley and 
Mandarino termed loss of this ability to switch easily between glucose and lipid 
oxidation metabolic inflexibility [5]. Obesity, insulin resistance and type 2 diabetes 
(T2D) are linked to reduced lipid oxidation during fasting, impaired postprandial 
switch from lipid to glucose oxidation and reduced capacity to increase lipid 
oxidation during exercise [3, 6-8]. Furthermore, a reduced postprandial switch from 
lipid to glucose oxidation has been observed in individuals with impaired glucose 
tolerance [7], suggesting that inflexibility plays a role in the early development of 
T2D. The usual way to measure metabolic flexibility to carbohydrate in vivo is to 
calculate the difference between steady-state respiratory quotient (RQ) at the end of 
hyperinsulinemic euglycemic clamp and fasting RQ (ΔRQ) [9]. A low RQ indicates 
high lipid oxidation, whereas a high RQ indicates high glucose oxidation. An 
impaired ability to increase muscle and whole body glucose oxidation during clamp 
has been observed in insulin resistant subjects [5, 10-12]. Additionally, insulin-
stimulated glucose disposal rate has been found to correlate with metabolic flexibility 
and to explain most of the variance in ΔRQ [11, 13], indicating that metabolic 
flexibility to carbohydrate is primarily reflecting glucose uptake. However, other 
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studies suggest that impairments in substrate uptake and oxidation do not always 
occur in parallel [1, 14]. Adaptability to lipid, i.e. the capacity to increase lipid 
oxidation upon increased fatty acid availability, is less thoroughly investigated. 
However, Kelley and Simoneau observed a higher postprandial leg RQ in response to 
a high-fat meal in T2D subjects compared to weight-matched non-diabetic controls 
[15]. 
 
Metabolic switching of skeletal muscle cells 
Metabolic switching of human skeletal muscle cells (myotubes) in vitro has been 
described by Ukropcova et al. [16]. Suppressibility was defined as the ability of the 
cells to suppress fatty acid (FA) oxidation by acute addition of glucose, and 
adaptability was defined as the capacity of the cells to increase FA oxidation upon 
increased fatty acid availability [16]. In vitro suppressibility was inversely correlated 
with insulin sensitivity and metabolic flexibility in vivo, whereas adaptability was 
positively correlated with these parameters [16]. This study indicated that metabolic 
switching is an intrinsic characteristic of skeletal muscle cells. Stull et al. recently 
showed that race was a contributor of metabolic flexibility in vivo [13], signifying that 
metabolic flexibility is at least partly a product of genetics. Nevertheless, metabolic 
inflexibility could be due to both intrinsic and extrinsic (induced) factors. Human in 
vivo studies have shown that postprandial impairments in metabolic flexibility can be 
improved by weight loss [7, 14, 17], and that exercise improves the ability of skeletal 
muscle to oxidize fatty acids during exercise and fasting [14, 18, 19]. A recent 
intervention study on men with metabolic syndrome indicated that isoenergetic 
modulation of dietary fat quality and quantity did not affect respiratory quotient or 
carbohydrate and lipid oxidation during fasting or after a meal [20]. However, the 
sample size in this study was relatively small for detecting such changes. The 
investigation of substrate oxidation started decades ago, and according to Randle 
cycle [21], fatty acids reduce glucose oxidation, whereas glucose reduces fatty acid 
oxidation through “reverse Randle cycle” [22, 23]. While the mechanistic basis for 
Randle cycle is relatively well understood, the molecular mechanism underlying 
metabolic inflexibility remains to be revealed.  
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Methodology used to measure metabolic switching of human myotubes  
For a better description of metabolic switching in cells, we have used three 
parameters, the two parameters suppressibility and adaptability as introduced by 
Ukropcova [16], and the new parameter substrate-regulated flexibility [24] in 
functional studies of fuel selection and energy metabolism in cell cultures. Substrate-
regulated flexibility was defined as the ability to increase fatty acid (FA) oxidation 
when changing from a high glucose (5 mM), low FA (5 µM) condition (“fed”) to a 
high FA (100 µM), low glucose (0 mM) (“fasted”) condition (Figure 1).  
The suppressibility of oleic acid (OA) oxidation, measured as carbondioxide 
formation (CO2), when 5 mM glucose was added acutely to the cells, was independent 
of the fatty acid concentration in the range from 5 to 300 µM (Figure 2A). Moreover, 
it was observed that maximum suppression by about 50 % was reached at 2-5 mM 
glucose, and already at 0.5-1 mM glucose acutely we observed a significant reduction 
in OA oxidation (IC50 0.55 mM). Moreover, we also showed that suppressibility of 
OA oxidation by glucose was not affected when increasing mitochondrial respiration 
by addition of the mitochondrial uncoupler 2.4-dinitrophenol (DNP) (Figure 2B). In 
the opposite situation, suppressibility of glucose oxidation by acute addition of OA 
was strongly dependent of mitochondrial respiration (Figure 2B) probably because 
glycolytic metabolism is preferred in human myotubes [25, 26]. 
The adaptability of OA oxidation in the range from 5 to 300 µM of the fatty acid is 
shown in Figure 2C, which demonstrate that the adaptability was dependent on FA 
concentration. For our calculations of this parameter we have mostly used the ratio 
100 µM FA/ 5 µM FA (Figure 1).  
Addition of insulin (100 nM) to the low FA condition (“fed”) condition did not 
change substrate-regulated flexibility, probably because most of the glucose uptake in 
human myotubes occurs independent of insulin. Moreover, Ukropcova et al. [16] 
observed that insulin was not needed for the expression of the metabolic switching 
phenotype in muscle cells. We also found that this parameter was robust against 
varying degree of fatty acid uptake by the cells (data not shown). The details about 
muscle cell cultures used in these studies are given in the legend to Figure 2. 
Metabolic switching of human myotubes can be changed by alterations in the 
extra-cellular milieu  
Metabolic switching of myotubes can be altered by changing the extracellular milieu, 
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and myotubes can be used as a cell model to determine how dietary changes (e.g. fatty 
acids), altered glycemic control (chronic hyperglycemia) or pharmacological agents 
acting at nuclear receptors (e.g. PPAR and LXR) may affect overall energy 
metabolism in cells. 
Treatment of myotubes with various fatty acids (100 µM) for 24 h showed that the n-3 
fatty acid eicosapentaenoic acid (EPA) increased suppressibility of the acute 
[14C]oleic acid (OA) metabolism compared to OA pretreatment, as well as 
adaptability and substrate-regulated flexibility compared to pretreatment with OA and 
the fatty acid-free control (BSA) (Figure 3 [24]). This suggests a beneficial role for 
EPA in improving metabolic switching and overall energy metabolism in skeletal 
muscle. Exposure of myotubes to other long-chain n-3 FAs such as α-linolenic acid 
(ALA) and docosahexaenoic acid (DHA) also increased substrate-regulated flexibility 
to the same extent as EPA, indicating that EPA’s effect on metabolic switching may 
be due to a general quality of n-3 FAs [24]. Adaptability of the myotubes was also 
increased after exposure to palmitic acid (PA) and linoleic acid (LA), suggesting that 
this is a general fatty acid effect. 
For most experiments we have used [14C]OA acutely when measuring the metabolic 
switching parameters. With OA pretreatment and subsequent incubation with 
[14C]OA we did not see any change in fatty acid adaptability for OA (Figure 4A). We 
also observed the same with PA pretreatment and [14C]PA thereafter, thus for 
determination of the adaptability parameter it seems that another FA acutely is 
preferred rather than the pretreatment fatty acid. The reason is not clear but it may be 
an artifact due to isotope dilution. Moreover, adaptability was much higher for 
labelled OA than for PA (Figure 4A). Also pretreatment with the sulfur-substituted 
fatty acid analogue tetradecylthioacetic acid (TTA) for 24 h and then using [14C]OA 
acutely increased the adaptability of the myotubes (Figure 4B). TTA may also work 
as a PPAR agonist after prolonged incubation of myotubes [27] (see later). 
In addition to various FAs, other components in the extracellular milieu can affect 
metabolic switching of myotubes. We have previously shown that treatment of human 
myotubes with chronic hyperglycemia (HG) reduced acute glucose uptake and 
glycogen synthesis. This reduction accompanied increased accumulation of TAG in 
the cells and an increased de novo lipogenesis [28]. Moreover, recent data show that 
HG reduced glucose and oleic acid (OA) oxidation, as well as the suppressibility of 
the cells [26]. However, the adaptability of OA oxidation was not affected after 
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chronic HG treatment [26]. We also measured substrate-regulated flexibility, which 
was significantly reduced after HG treatment of the cells (Figure 5).  
 
Metabolic switching of human myotubes can be modified by agonist regulating 
the nuclear receptors PPARs and LXRs  
In addition to various FAs and chronic hyperglycemia, we also examined the possible 
involvement of peroxisome proliferator-activated receptors (PPARs) and liver X 
receptors (LXRs) in metabolic switching. The myotubes were incubated for 4 days 
with compounds known to act agonistic at these receptors. 
PPARs are activated by fatty acids and therefore act as lipid sensors in the body [29-
31]. Three subtypes of PPARs have been identified, differing in tissue distribution 
and function. PPARα is predominantly expressed in the liver, but also found in heart 
and skeletal muscle, where it increases fatty acid oxidation [29, 32-34]. PPARγ is 
mainly expressed in adipose tissue, and plays an important role in adipocyte 
differentiation and lipid storage [31, 35-37]. In contrast to the other subtypes, PPARδ 
(also called PPARβ) is ubiquitously expressed and is relatively abundant in skeletal 
muscle [38]. The human myotube model used in our experiments express more 
PPARδ than PPARα (unpublished observations).  
The role of PPARδ is currently under investigation, and is so far found to increase 
fatty acid oxidation in skeletal muscle [39], and might thus play an important role in 
energy turnover [40]. Treatment of the myotubes with the PPARδ agonists 
GW501516 and the pan-agonist TTA for 4 days during differentiation increased CO2 
formation from the cells when incubated acutely with labelled OA (Figure 6). The 
two metabolic parameters suppressibility and adaptability were not changed by PPAR 
activation, but substrate-regulated flexibility was 2-fold increased by TTA (Figure 7), 
but not by GW501516. TTA is a pan-PPAR activator that reduces plasma lipids and 
enhances hepatic fatty acid oxidation in rodents [41]. Dual and pan-PPAR agonists 
are currently being developed for treatment of type 2 diabetes (T2D) [42], and TTA 
has been shown to improve glucose metabolism in insulin-resistant rats [43] and to 
stimulate mitochondrial proliferation in rat skeletal muscle [44]. Recently, we have 
shown that preincubation of myotubes with TTA enhanced mitochondrial fatty acid 
and glucose oxidation, indicating increased mitochondrial biogenesis and an 
improved glucose metabolism [27]. At the same time TTA opposed increased lipid 
accumulation by the cells. TTA seems more potent in activating rat PPARα than 
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PPARδ [43, 45], whereas the opposite has been demonstrated for human PPARs [46]. 
This may partly explain why TTA has particularly strong effects on hepatic 
metabolism in rodents where PPARα is a major regulator, but relatively modest 
effects in skeletal muscle where PPARδ may play a more prominent role [38, 47]. In 
human myotubes, PPARδ seems to play a dominant role over PPARα in controlling 
lipid oxidation [48], and we have demonstrated that preincubation of myotubes with 
the PPARδ selective agonist GW501516 and TTA, but not the PPARα-selective 
agonists fenofibrate and clofibrate (at PPARα-selective concentrations), could induce 
increased mitochondrial fatty acid oxidation in myotubes [49]. Our data on fatty acid 
oxidation (Figure 6) also demonstrate that an increased capacity for oxidation of fatty 
acids (increased CO2 formation) alone is not sufficient to change the metabolic 
parameters described in this paper.  
LXRs play a crucial role in regulation of cholesterol, lipid and carbohydrate 
metabolism [50-54]. We have shown that chronic activation of LXRs may affect 
glucose uptake and oxidation as well as promote a strong effect on lipid metabolism 
by increasing fatty acid uptake and accumulation as complex lipids and to stimulate 
lipogenesis in human myotubes [55, 56]. Thus, LXRs could play a role in the 
regulation of metabolic switching. We have shown that treatment of myotubes with 
the LXR agonist T0901317 for 2 days did not affect suppressibility or adaptability of 
the cells per se, but counteracted the effect of EPA on these two parameters (Figure 
8A and B, [24]). Treatment with T0901317 did not change substrate-regulated 
flexibility, nor cancel out the effect of EPA on this parameter. Therefore, LXRs do 
not seem to play a major role, but show some impact on metabolic switching of 
myotubes.   
 
Possible mechanisms for changes in metabolic switching of myotubes 
To study whether the effects of FA pretreatment on metabolic switching could be due 
to altered gene expression, microarray analysis was performed [24]. This revealed that 
24 h treatment with 0.1 mM EPA regulated more genes than the other FAs examined, 
followed by LA and OA, while PA regulated fewest genes. Three of the genes 
induced by all FAs are involved in fatty acid β-oxidation [24]. Hence, this could 
reflect the ability of FAs to increase adaptability. Moreover, pathway analysis showed 
that some pathways involved in carbohydrate metabolism were affected only after 
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exposure to EPA, supporting the functional data showing specific effects of n-3 FAs 
on suppressibility and substrate-regulated flexibility compared to the other FAs [24] 
(Figure 9). In vivo studies (both human and animal) have shown that fatty acid 
oxidation and the activity of β-oxidation enzymes are increased in skeletal muscle of 
individuals/rats fed a high-fat diet [57-59]. This could be a mechanism to compensate 
for elevated availability of fatty acids to protect against lipid accumulation, and might 
be reflected in vitro by the adaptability parameter.   
Chronic treatment with the PPARδ agonist GW501516 markedly increased OA 
oxidation and this substance has previously been shown to induce genes involved in 
fatty acid transport and oxidation in cells [39, 48, 60], and to increase fatty acid 
oxidation [61, 62]. Moreover, we demonstrate that increasing the capacities for fatty 
acid oxidation by PPAR activation, or respiration by mitochondrial uncoupling did 
not change the metabolic parameters in the myotubes. The pan-PPAR agonist TTA 
also increased fatty acid oxidation, but in contrast to GW501516 it seemed to increase 
substrate-regulated flexibility. We have previously shown that TTA also positively 
influences glucose metabolism in myotubes [27], and this fatty acid analogue also 
increased adaptability after 24 h pretreatment (Figure 4B). Thus, TTA may show 
PPAR and PPAR-independent effects [41, 45] in myotubes that could explain the 
difference between the two PPAR agonists on the metabolic parameters.  With respect 
to the different FAs some studies have shown that PUFAs are slightly more potent 
PPAR agonists than other FAs [29, 30, 63], however no difference in the activation of 
PPARs has been observed between n-3 and n-6 FAs [29, 63]. Studies have indicated 
that PPARα interacts almost equally with both saturated and unsaturated FAs and that 
PPARδ also interacts with saturated and unsaturated FAs, although less effective than 
PPARα [63, 64]. Based on the gene expression studies we suggest that the effects on 
metabolic switching by FAs may only partly be explained by changes in gene 
expression [24].  
The effects of distinct FAs on metabolic switching could also be due to differences in 
accumulation of fatty acids, the level of intracellular lipid species such as acyl-CoA, 
diacylglycerol (DAG) and triacylglycerol (TAG), and lipid utilization. Ectopic fat 
deposition is associated with impaired organ function [65], and increased 
accumulation of intramyocellular lipids (IMCL) correlates with insulin resistance and 
T2D [66-70]. Intramyocellular lipid intermediates might as well affect metabolic 
switching. We have shown that EPA per se was less incorporated in the cells than the 
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other FAs examined, probably due to higher oxidation rate [24]. However, treatment 
with EPA, as well as OA and LA, increased the number of lipid droplets (LDs) per 
nucleus in myotubes [24]. The content of neutral lipids followed the same pattern as 
the number of LDs, but lipid distribution was not changed by pretreatment with the 
various FAs. In accordance with our data, previous studies have shown that treatment 
with EPA increased acute fatty acid uptake [27, 71]. Furthermore, treatment with EPA 
has been shown to promote accumulation of TAG and reduce the level of total acyl-
CoA in human myotubes [27, 71]. Nevertheless, although various FAs were handled 
differently in the cells, altered lipid specie distribution could not easily explain the 
observed effects on metabolic switching. Other possible mechanisms by which 
metabolic switching can be changed by FAs include altered AMP-activated protein 
kinase (AMPK) activity, differences in gene regulation through various nuclear 
receptors, as well as different membrane incorporation of fatty acids and thereby 
altered membrane fluidity and activity of membrane-associated proteins or dynamics 
of mitochondrial membranes [72-79].  
The effects of chronic hyperglycemia (HG) on metabolic switching were not due to 
changes in gene expression, as microarray analysis revealed that no genes were 
significantly regulated by HG treatment [26]. This is a potential important finding, 
and suggests that the effects of HG could be due to post-translational modifications, 
such as glycosylations or glycations. Moreover, ATP concentration was reduced in 
HG cells. This indicates that hyperglycemia induces some kind of mitochondrial 
dysfunction. The amount of mitochondrial DNA was not changed indicating that the 
mitochondrial content was unaffected. Yet, the mitochondrial function might be 
impaired. This is in accordance with the findings of Gao et al. showing that HG 
treatment of 3T3-L1 adipocytes induced insulin resistance, loss of mitochondrial 
membrane potential, as well as resulted in smaller and more compact mitochondria 
with no effect on mitochondrial DNA [80]. Another mechanism by which HG 
theoretically could affect metabolism is through altered AMPK activity, since glucose 
infusion in rats has been shown to reduce phosphorylation of AMPK and its substrate 
acetyl-CoA carboxylase (ACC) in red but not white muscle [81]. In our study [26], 
AMPK activity could not explain the metabolic impairments because phosphorylation 
of AMPK and ACC was not changed after HG exposure. Taken together, chronic HG 
impaired metabolic switching of myotubes probably due to an induced mitochondrial 
dysfunction. 
  10 
Conclusion 
The in vitro metabolic parameters suppressibility, adaptability and substrate-regulated 
flexibility can be modified by fatty acids or by chronic hyperglycemia (HG) in human 
myotubes. Eicosapentaenoic acid (EPA) increased all three parameters, and the effect 
of EPA could be counteracted by LXR activation. The fatty acid analogue 
tetradecylthioacetic acid (TTA) could also modify metabolic switching depending on 
treatment time. Increased fatty acid oxidation after PPARδ agonist treatment did not 
change metabolic switching of myotubes. Treatment with HG negatively influenced 
suppressibility and substrate-regulated flexibility of the cells. 
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Captions to illustrations 
 
Figure 1. Calculations of metabolic flexibility parameters. 
 
Figure 2. Suppressibility of oleic acid (OA) oxidation by glucose and of glucose 
oxidation by OA, and adaptability of OA oxidation at different OA 
concentrations. Suppressibility (A). Myotubes underwent CO2 trapping for 4 h with 
different concentrations of [14C]oleic acid (OA) in the presence or absence of 5 mM 
glucose. Suppressibility with mitochondrial uncoupling (B). Myotubes were incubated 
with radiolabeled substrates in the absence or presence of 2.4-dinitrophenol (DNP, 
100 µM) for 4 h to collect CO2. Figure shows suppressibility by acute glucose or by 
acute oleic acid. Figure left shows suppressibility of [14C]oleic acid (OA) (100 µM) 
oxidation in presence of acute glucose (5 mM), and right shows suppressbility of 
[14C(U)]glucose (200 µM) oxidation in presence of acute OA (100 µM). Adaptability 
(C). Myotubes underwent CO2 trapping for 4 h with different concentrations of 
[14C]OA in the absence of glucose. Results represent means ± SEM for n=5 (A), n=4 
(B), n=4-17 (C). n, number of separate experiments with cells from individual donors.  
Human skeletal muscle cell cultures. Satellite cells were isolated from the M. 
obliquus internus abdominis of healthy donors. The biopsies were obtained with 
informed consent and approval by the regional committee for research ethics, Oslo, 
Norway. The cells were cultured in DMEM (5.5 mM glucose) with 2% foetal calf 
serum (FCS), 2% Ultroser G, penicillin/streptomycin (P/S) and amphotericin B until 
70-80% confluent. Myoblast differentiation to myotubes was then induced by 
changing medium to DMEM (5.5 mM glucose) with 2% FCS, 25 pM insulin, P/S and 
amphotericin B. Experiments were performed after 7-8 days of differentiation. 
 
Figure 3. Suppressibility of oleic acid (OA) oxidation by glucose, adaptability of 
OA oxidation and substrate-regulated flexibility of OA after pretreatment with 
different fatty acids.  Suppressibility (A). Myotubes were pretreated for 24 h with 
100 µM OA, EPA, LA, PA, 40 µM BSA (control, all FA treatments contain 40 µM 
bovine serum albumin, BSA), and thereafter underwent CO2 trapping for 4 h with 100 
µM [14C]oleic acid (OA) in the presence or absence of 5 mM glucose. Adaptability 
(B). Myotubes were pretreated for 24 h with 100 µM OA, EPA, LA, PA, 40 µM BSA 
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(control), and thereafter underwent CO2 trapping for 4 h with 5 or 100 µM [14C]OA in 
the absence of glucose. Substrate-regulated flexibility (C). Myotubes were pretreated 
for 24 h with 100 µM OA, EPA, LA, PA, 40 µM BSA (control), and thereafter 
underwent CO2 trapping for 4 h with 100 µM [14C]OA in the absence of glucose or 
with 5 µM [14C]OA in the presence of 5 mM glucose. Results represent means ± SEM 
for n=11-17 (A), n=6-12 (B), n=6-12 (C). *p<0.05 vs. control, #p<0.05 vs oleic acid 
(t-test). 
Abbreviations: BSA, bovine serum albumin; EPA, eicosapentaenoic acid; LA, 
linoleic acid; OA, oleic acid; PA, palmitic acid. Reproduced from [24]. 
 
Figure 4. Adaptability of fatty acid oxidation. Myotubes were pretreated for 24 h 
with 100 µM OA, PA or 40 µM BSA (control), and thereafter underwent CO2 
trapping for 4 h with 5 or 100 µM [14C]OA or [14C]PA in the absence of glucose (A). 
Myotubes were pretreated for 24 h with 100 µM tetradecylthioacetic acid (TTA), and 
thereafter underwent CO2 trapping for 4 h with 5 or 100 µM [14C]OA in the absence 
of glucose. Results represent means ± SEM for n=5 (A and B). *p<0.05 vs. control. 
 
Figure 5. Substrate-regulated flexibility after chronic hyperglycemia (HG). 
Myotubes were pretreated for 4 days with 20 mM glucose, and thereafter the cells 
underwent CO2 trapping for 4 h with 100 µM [14C]OA in the absence of glucose or 
with 5 µM [14C]OA in the presence of 5 mM glucose. Results represent means ± SEM 
for n=4. *p<0.05 vs. control.  
 
Figure 6. Carbondioxide formation after pretreatment with PPAR agonists. 
Myotubes were pretreated for 4 days with 100 µM tetradecylthioacetic acid (TTA), 10 
nM GW501516 or vehicle (control, DMSO), and thereafter the cells underwent CO2 
trapping for 4 h with 100 µM [14C]oleic acid (OA) in the absence of glucose. Results 
represent means ± SEM for n=3-7. *p<0.05 vs. control. 
 
Figure 7. Suppressibility of oleic acid (OA) oxidation by glucose, adaptability of 
OA oxidation and substrate-regulated flexibility of OA after pretreatment with 
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PPAR agonists. Suppressibility (A). Myotubes were pretreated for 4 days with 100 
µM tetradecylthioacetic acid (TTA), 10 nM GW501516 or vehicle (control, DMSO), 
and thereafter the cells underwent CO2 trapping for 4 h with 100 µM [14C]oleic acid 
(OA) in the presence or absence of 5 mM glucose. Adaptability (B). Myotubes were 
pretreated for 4 days with 100 µM tetradecylthioacetic acid (TTA), 10 nM 
GW501516 or vehicle (control, DMSO), and thereafter the cells underwent CO2 
trapping for 4 h with 5 or 100 µM [14C]OA in the absence of glucose. Substrate-
regulated flexibility (C). Myotubes were pretreated for 4 days with 100 µM 
tetradecylthioacetic acid (TTA), 10 nM GW501516 or vehicle (control, DMSO), and 
thereafter the cells underwent CO2 trapping for 4 h with 100 µM [14C]OA in the 
absence of glucose or with 5 µM [14C]OA in the presence of 5 mM glucose. Results 
represent means ± SEM for n=8, 3, 3 for A, B, C, respectively.  
 
Figure 8. Suppressibility of oleic acid (OA) oxidation by glucose, adaptability of 
OA oxidation and substrate-regulated flexibility of OA after pretreatment with 
eicosapentaenoic acid (EPA) and a LXR agonist T0901317. Suppressibility (A). 
Myotubes were pretreated for 24 h with 1 µM T0901317 or vehicle (DMSO), and 
then for another 24 h with 100 µM EPA or 40 µM BSA (control) with and without 
T0901317, and thereafter the cells underwent CO2 trapping for 4 h with 100 µM 
[14C]oleic acid (OA) in the presence or absence of 5 mM glucose. Adaptability (B). 
Myotubes were pretreated for 24 h with 1 µM T0901317 or vehicle (DMSO), and 
then for another 24 h with 100 µM EPA or 40 µM BSA (control) with and without 
T0901317, and thereafter the cells underwent CO2 trapping for 4 h with 5 or 100 µM 
[14C]OA in the absence of glucose. Substrate-regulated flexibility (C). Myotubes were 
pretreated for 24 h with 1 µM T0901317 or vehicle (DMSO), and then for another 24 
h with 100 µM EPA or 40 µM BSA (control) with and without T0901317, and 
thereafter the cells underwent CO2 trapping for 4 h with 100 µM [14C]OA in the 
absence of glucose or with 5 µM [14C]OA in the presence of 5 mM glucose. Results 
represent means ± SEM for n=6-17, 6-12, 6-12 for A, B, C, respectively. *p<0.05 vs. 
control, #p<0.05 vs EPA.  
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Figure 9. Pathways involved in metabolic processes upregulated by fatty acids in 
myotubes. Myotubes were incubated with fatty acids (100 µM) or control (BSA 40 
µM) for 24 h and harvested for RNA isolation. Gene expression was measured by 
Affymetrix human NuGO Genechip arrays and gene set enrichment analysis (GSEA) 
was performed to identify pathways regulated by OA, PA, LA, and EPA compared to 
control. Pathways with FDR (q-value) < 0.2, that is –log(q) > 0.7, were considered 
significantly regulated. Line marks –log(q) = 0.7, the cut-off for significance for the 
GSEA. In short, GSEA identifies pathways in which more genes are regulated than 
one would expect on the basis of chance. 
Abbreviations: BSA, bovine serum albumin; EPA, eicosapentaenoic acid; LA, 
linoleic acid; OA, oleic acid; PA, palmitic acid. Reproduced from reference [24]. 
 
Figure 10.  Metabolic switching of myotubes. The metabolic parameters 
suppressibility, adaptability and substrate-regulated flexibility can be modified by 
fatty acids or by chronic hyperglycemia (HG). Eicosapentaenoic acid (EPA) increased 
all three parameters, and the effect of EPA could be counteracted by LXR activation. 
The fatty acid analogue and PPAR activator tetradecylthioacetic acid (TTA) could 
also modify metabolic switching depending on treatment time. Treatment of 
myotubes with HG negatively influenced suppressibility and substrate-regulated 
flexibility. 
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Suppressibility: the ability of the cells to decrease oleic 
acid (OA) oxidation by acutely added glucose:  
[(1-(oxidation of 100 µM OA at 5 mM glucose/oxidation 
of 100 µM OA at no glucose added)) × 100 %].  
Adaptability: the ability to increase the OA oxidation 
with increasing OA concentration:  
[oxidation of 100 µM OA/oxidation of 5 µM OA].  
Substrate-regulated flexibility: the ability to increase 
the OA oxidation while changing from the "fed" (low 
fatty acid, high glucose) to the "fasted" (high fatty acid, 
no glucose added) condition:  
[oxidation of 100 µM OA without glucose added/ 
oxidation of 5 µM OA at 5 mM glucose].  
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